Prognostic value of ischaemia-modified albumin in patients with non-ST-segment elevation acute coronary syndromes

Archives of Cardiovascular Diseases

Volumn 101, Issue 10, 2008, Pages 645-651

  Bali, Laurent ^a   Cuisset, Thomas ^a   Giorgi, Roch ^a   Monserrat, Colette ^a   Quilici, Jacques ^a   Carrega, Louis ^a   Mouret, Jean Philippe ^a   Nait Saidi, Lyassine ^a   Mielot, Christopher ^a   Lambert, Marc ^a   Guieu, Régis ^a   Bonnet, Jean Louis ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

Acute coronary syndrome; Ischaemia modified albumin; Prognostic value

Indexed keywords

C REACTIVE PROTEIN; ISCHEMIA MODIFIED ALBUMIN; TROPONIN I;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; THORAX PAIN;

EID: 57849153031     PISSN: 18752136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acvd.2008.09.005     Document Type: Article

References (25)

1. Heidenreich PA, Alloggiamento T, Melsop K, et al. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol 2001;38:478-85.
2. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417-24.
3. Morrow DA, de Lemos JA, Sabatine MS, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/ non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003;41:1264-72.
4. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
5. Peacock F, Morris DL, Anwaruddin S, et al. Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. Am Heart J 2006;152:253-62.
6. Roy D, Quiles J, Aldama G, et al. Ischemia modified albumin for the assessment of patients presenting to the emergency department with acute chest pain but normal or nondiagnostic 12-lead electrocardiograms and negative cardiac troponin T. Int J Cardiol 2004;97:297-301.
7. Sinha MK, Roy D, Gaze DC, et al. Role of "ischemia modified albumin", a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg Med J 2004;21:29-34.
8. Roy D, Quiles J, Sharma R, et al. Ischemia-modified albumin concentrations in patients with peripheral vascular disease and exercise-induced skeletal muscle ischemia. Clin Chem 2004;50:1656-60.
9. Lagabrielle JF, Delarche N, Adamou TH. Proportioning of the albumin modified by ischemia (IMA) within the framework of programmed angioplasties. Immuno-analyse et Biologie specialisee 2005;20:221-7.
10. Sinha MK, Gaze DC, Tippins JR, et al. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation 2003;107:2403-5.
11. Bar-Or D, Winkler JV, Vanbenthuysen K, et al. Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: a preliminary comparison to creatine kinase-MB, myoglobin, and troponin I. Am Heart J 2001;141:985-91.
12. Sharma R, Gaze DC, Pellerin D, et al. Ischemia-modified albumin predicts mortality in ESRD. Am J Kidney Dis 2006;47:493-502.
13. Worster A, Devereaux PJ, Heels-Ansdell D, et al. Capability of ischemia-modified albumin to predict serious cardiac outcomes in the short term among patients with potential acute coronary syndrome. CMAJ 2005;172:1685-90.
14. Dusek J, St'asek J, Tichy M, et al. Prognostic significance of ischemia modified albumin after percutaneous coronary intervention. Clin Chim Acta 2006;367:77-80.
15. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000;102:2031-7.
16. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. 2002: Summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002;106: 1893-900.
17. Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, in Collaboration with the Society of Chest Pain CentersGibler WB, Cannon CP, Blomkalns AL, et al. Practical implementation of the guidelines for unstable angina/ non-ST-segment elevation myocardial infarction in the emergency department: a scientific statement from the American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care). Circulation 2005;111:2699-710.
18. Carrega L, Giaime P, Montserrat C, et al. Influence of the dialysis membrane on markers of tissue ischemia. J Investig Med 2006;54:62-6.
19. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598-660.
20. Mandelzweig L, Battler A, Boyko V, et al. The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J 2006;27: 2285-93.
21. Chang WC, Midodzi WK, Westerhout CM, et al. Are international differences in the outcomes of acute coronary syndromes apparent or real? A multilevel analysis. J Epidemiol Community Health 2005;59:427-33.
22. Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006;333: 1091-4.
23. Bodi V, Sanchis J, Llacer A, et al. Multimarker risk strategy for predicting 1-month and 1-year major events in non-ST-elevation acute coronary syndromes. Am Heart J 2005;149:268-74.
24. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002;105:1760-3.
25. Ridker PM. Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) in clinical practice. Am Heart Hosp J 2004;2:4-9.